文献速递血脂与心血管预防

起始LDL-C极低患者进一步降脂的疗效与安全性:荟萃分析

Efficacy and Safety of Further Lowering of Low-Density Lipoprotein Cholesterol in Patients Starting With Very Low Levels: A Meta-analysis.
PubMed 文献 · JAMA Cardiol · 2018-01-01

该荟萃分析基于胆固醇治疗试验协作组(CTTC)他汀数据及3项非他汀心血管结局试验,评估起始中位LDL-C≤1.8 mmol/L(70 mg/dL)人群进一步降低LDL-C的疗效与安全性。每降低1 mmol/L(38.7 mg/dL),主要血管事件风险比在他汀亚组为0.78(95%CI 0.65-0.94),非他汀试验为0.79(95%CI 0.70-0.88),合并为0.79(95%CI 0.71-0.87;P<.001),未观察严重不良事件风险增加。

要点

  • 起始LDL-C已很低者,每降1 mmol/L主要血管事件风险仍降约21%。
  • 他汀与非他汀联合分析风险比0.79(95%CI 0.71-0.87;P<.001)。
  • 进一步降LDL-C未增加严重不良事件、肌痛/肌炎、糖尿病等风险。

核心结论

  • 在起始中位LDL-C低至1.6 mmol/L(63 mg/dL)并降至中位0.5 mmol/L(21 mg/dL)的人群中,每降低1 mmol/L LDL-C主要血管事件相对风险一致降低,且未观察到抵消性不良反应。

研究设计与样本

  • 他汀数据来自CTTC荟萃分析中对照组平均LDL-C为1.7 mmol/L(65.7 mg/dL)的亚组。
  • 非他汀数据检索Medline(2015年至2018年4月),纳入3项在スタチン基础上加用非他汀降脂药的随机双盲对照心血管结局试验,共50 627例患者,对照组中位LDL-C 1.6-1.8 mmol/L(63-70 mg/dL)。

主要发现

  • CTTC他汀亚组发生1922例主要血管事件,每降低1 mmol/L LDL-C的风险比(RR)为0.78(95%CI 0.65-0.94)。
  • 非他汀试验中非他汀治疗降低LDL-C 0.3-1.2 mmol/L(11-45 mg/dL),发生9570例主要血管事件,每降低1 mmol/L的RR为0.79(95%CI 0.70-0.88)。
  • 他汀与非他汀合并分析,每降低1 mmol/L LDL-C的RR为0.79(95%CI 0.71-0.87;P<.001)。
  • 降低LDL-C未与严重不良事件、肌痛和/或肌炎、转氨酶升高、新发糖尿病、出血性卒中或癌症风险增加相关。

关键数值与推荐

  • 主要血管事件定义为冠心病死亡、心肌梗死、缺血性卒中或冠状动脉血运重建的复合终点。
  • 疗效尺度为LDL-C每降低1 mmol/L(38.7 mg/dL)的主要血管事件风险比。

临床怎么用

  • 对已接受降脂治疗且LDL-C已达当前最低目标值的患者,可考虑进一步降低LDL-C以进一步降低心血管风险。
  • 进一步降脂时无需因严重不良事件、肌痛/肌炎、转氨酶升高、新发糖尿病、出血性卒中或癌症风险而顾虑。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: In the Cholesterol Treatment Trialists Collaboration (CTTC), in patients starting with low-density lipoprotein cholesterol (LDL-C) levels of approximately 3.4 mmol/L (131.5 mg/dL), there was a 22% reduction in major vascular events per 1-mmol/L (38.7-mg/dL) lowering of LDL-C. The magnitude of clinical benefit of further LDL-C lowering in patients already with very low LDL-C levels remains debated. OBJECTIVE: To evaluate efficacy and safety of further lowering LDL-C levels in patient populations presenting with median LDL-C levels of 1.8 mmol/L (70 mg/dL) or less. DATA SOURCES AND STUDY SELECTION: The CTTC was used for statin data. For nonstatin therapy, Medline database was searched (2015-April 2018). Key inclusion criteria were a randomized, double-blind, controlled cardiovascular outcome trial of LDL-C lowering with data in populations starting with LDL-C levels averaging 1.8 mmol/L (70 mg/dL) or less. DATA EXTRACTION AND SYNTHESIS: Two authors independently extracted data into standardized data sheets, and data were analyzed using meta-analysis. MAIN OUTCOMES AND MEASURES: The risk ratio (RR) of major vascular events (a composite of coronary heart death, myocardial infarction, ischemic stroke, or coronary revascularization) per 1-mmol/L (38.7-mg/dL) reduction in LDL-C level. RESULTS: In the subgroup of patients from the CTTC meta-analysis of statins with a mean LDL-C in the control arm of 1.7 mmol/L (65.7 mg/dL), 1922 major vascular events occurred and the RR for major vascular events per 1-mmol/L (38.7-mg/dL) reduction in LDL-C was 0.78 (95% CI, 0.65-0.94). For 3 trials of nonstatin LDL-C-lowering therapies added to statins, there were 50 627 patients, the median LDL-C in the control arms ranged from 1.6 mmol/L to 1.8 mmol/L (63 mg/dL to 70 mg/dL), and 9570 major vascular events occurred. Nonstatin therapy lowered LDL-C by 0.3 to 1.2 mmol/L (11 mg/dL to 45 mg/dL), and the RR for major vascular events per 1-mmol/L (38.7-mg/dL) reduction in LDL-C was 0.79 (95% CI, 0.70-0.88). For statins and nonstatins combined, the RR was 0.79 (95% CI, 0.71-0.87; P < .001). Low-density lipoprotein cholesterol lowering was not associated with an increased risk of serious adverse events, myalgias and/or myositis, elevation in the level of aminotransferases, new-onset diabetes, hemorrhagic stroke, or cancer. CONCLUSIONS AND RELEVANCE: There is a consistent relative risk reduction in major vascular events per change in LDL-C in patient populations starting as low as a median of 1.6 mmol/L (63 mg/dL) and achieving levels as low as a median of 0.5 mmol/L (21 mg/dL), with no observed offsetting adverse effects. These data suggest further lowering of LDL-C beyond the lowest current targets would further reduce cardiovascular risk.

来源:JAMA Cardiol,查看原文。版权归原作者所有。

引用

  1. Sabatine MS, Wiviott SD, Im K, et al. Efficacy and Safety of Further Lowering of Low-Density Lipoprotein Cholesterol in Patients Starting With Very Low Levels: A Meta-analysis. JAMA Cardiol. 2018. PMID: 30073316. doi:10.1001/jamacardio.2018.2258

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。